Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Samantha Gonzalez

Physician Assistant Sun City, AZ Physician Assistant

NPI 1891263752 CMS profile 10529620

13203 N 103Rd Ave Ste H5, Sun City, AZ 85351

Open in the dashboard

General payments

$2,501

115 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samantha Gonzalez of Sun City, AZ is reported in the CMS Open Payments database as having received $2,501 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $593 18
2024 General $805 30
2023 General $415 17
2022 General $150 8
2021 General $539 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samantha Gonzalez
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Samantha Gonzalez were reported at $593. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Samantha Gonzalez Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $539 $132 $37–$438 $132
2022 $150 $155 $48–$522 $149
2023 $415 $167 $52–$557 $160
2024 $805 $178 $55–$600 $164
2025 $593 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. BIOTRONIK NRO, Inc. $656 21 payments
  2. Boston Scientific Corporation $382 21 payments
  3. Nevro Corp. $208 24 payments
  4. Spinal Simplicity, LLC $184 3 payments
  5. Medtronic, Inc. $160 2 payments
  6. Nalu Medical, Inc. $157 6 payments
  7. Painteq LLC $151 2 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $131 8 payments
  9. AbbVie, Inc. $119 7 payments
  10. Collegium Pharmaceutical, Inc. $81 5 payments
  11. Other $272 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,501 115 payments
Products named General payments · program years 2021–2025
  1. Prospera Not Applicable $353 13 payments
  2. Prospera Not Applicable $263 6 payments
  3. Omnia $208 24 payments
  4. HA MINUTEMAN G3-R $184 3 payments
  5. Nalu Neurostimulation System $157 6 payments
  6. PAINTEQ $151 2 payments
  7. INTELLIS ADAPTIVESTIM $116 1 payment
  8. RELISTOR $115 7 payments
  9. General - Pain Management $96 5 payments
  10. UBRELVY $67 4 payments
  11. Other $701 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

3,876

Median for Physician Assistant: 241

Drug cost

$214,144

Median for Physician Assistant: $4,110

Branded share of claims

47.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 16 $41,388
Percocet Oxycodone Hcl/Acetaminophen Brand 12 $36,328
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 906 $21,338
Xtampza Er Oxycodone Myristate Brand 28 $20,178
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 645 $17,386
Belbuca Buprenorphine Hcl Brand 16 $15,061
Buprenorphine Generic 40 $9,771
Oxycontin Oxycodone Hcl Brand 18 $9,475
Movantik Naloxegol Oxalate Brand 18 $6,731
Oxycodone Hcl Generic 333 $6,263

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$27,510

Medicare's payments for the services billed

Medicare patients

160

Average age 76

Services billed

390

105 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 36%
Depression 34%
Ischemic heart disease 29%
Diabetes 27%
COPD 26%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $49
$49 16 —
MOVANTIK
  • Valinor Pharma, LLC $41
$41 18 —
ZTLido
  • Scilex Pharmaceuticals Inc. $17
$17 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $16
$16 28 —
BELBUCA
  • Collegium Pharmaceutical, Inc. $16
$16 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record